Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 10/20 | 0.67 |
| ▸ | MMP2 | P08253 | 10/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.67 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MMP1 | P03956 | 1/20 | 0.60 |
| ▸ | MMP3 | P08254 | 1/20 | 0.60 |
| ▸ | MMP7 | P09237 | 1/20 | 0.60 |
| ▸ | MMP13 | P45452 | 1/20 | 0.60 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561566 | 1.00 | MMP9 (0.67) | MMP9MMP2TDP1ADAMTS4ADAMTS5 | |
| Chloromethane SCHEMBL7649372 | 0.91 | MMP2 (0.75) | MMP9MMP2TDP1ADAMTS4ADAMTS5 | |
| SCHEMBL1203540 | 0.91 | MMP2 (0.79) | MMP9MMP2TDP1ADAMTS4ADAMTS5 | |
| SCHEMBL697476 | 0.91 | MMP2 (0.79) | MMP9MMP2TDP1ADAMTS4ADAMTS5 | |
| SCHEMBL697477 | 0.91 | MMP2 (0.79) | MMP9MMP2TDP1ADAMTS4ADAMTS5 | |
| SCHEMBL3856155 | 0.90 | MMP2 (0.73) | MMP9MMP2TDP1ADAMTS4ADAMTS5 | |
| Hydrochloric Acid SCHEMBL3839410 | 0.90 | MMP2 (0.77) | MMP9MMP2TDP1ADAMTS4ADAMTS5 | |
| Hydrochloric Acid SCHEMBL11133046 | 0.90 | MMP2 (0.77) | MMP9MMP2TDP1ADAMTS4ADAMTS5 | |
| SCHEMBL433895 | 0.89 | MMP9 (0.69) | MMP9MMP2TDP1ADAMTS4ADAMTS5 | |
| SCHEMBL1523717 | 0.89 | MMP9 (0.69) | MMP9MMP2TDP1ADAMTS4ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2819665-B1 | PROTEASE INHIBITORS FOR TREATING TRICHOMONAS GALLINAE INFECTIONS | VETERINÄRMEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2017-02-22 | — | — | EP | claimed |
| EP-2633855-A1 | Protease inhibitors for treating Trichomonas gallinae infections | Veterinärmedizinische Universität Wien (AT) | 2013-09-04 | — | — | EP | claimed |
| WO-2010003037-A2 | COMPOSITIONS, SYSTEMS, AND METHODS FOR STABILIZATION OF A CELL AND/OR MACROMOLECULE | SIERRA MOLECULAR CORPORATION (US) | 2010-01-07 | — | — | WO | claimed |
| US-20100003748-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR STABILIZATION OF A CELL AND/OR MACROMOLECULE | SIERRA MOLECULAR CORPORATION | 2010-01-07 | — | — | US | claimed |
| WO-2008029965-A1 | SIMULTANEOUS REACTION ASSAY FOR DIFFERENTIALLY DETECTING MULTIMERIC FORM | PEOPLEBIO, INC. (KR) | 2008-03-13 | — | — | WO | claimed |
| US-5518912-A | A PURE ENZYME ENDOGENOUS TO BIOLOGICAL CELLS OF THE SKIN OF XENOPUS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 1996-05-21 | — | — | US | claimed |
| US-20250268748-A1 | TREATMENT OF SPINAL MUSCULAR ATROPHY BY INDUCING HEAT SHOCK RESPONSE | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN’S HOSPITAL | 2025-08-28 | — | — | US | disclosed |
| US-20250195630-A1 | COMPOSITIONS, METHODS AND USES OF ALPHA 1-ANTITRYPSIN FOR TREATMENT OF GRAFT VERSUS HOST DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-06-19 | — | — | US | disclosed |
| US-20250186563-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2025-06-12 | — | — | US | disclosed |
| EP-3604510-B1 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240189401-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240082367-A1 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2024-03-14 | — | — | US | disclosed |
| CN-115364021-B | A cream containing supercritical plant extract and its preparation method | 广州市百爱神生物科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-4634671-A | SEMI-SYNTHESIS OF HUMAN INSULIN | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1987-01-06 | — | — | US | disclosed |
| US-4511505-A | THREONINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1985-04-16 | — | — | US | disclosed |
| EP-0085083-B1 | PROCESS FOR THE ENZYMATIC PREPARATION OF HUMAN INSULIN | NORDISK INSULINLABORATORIUM (DK) | 1985-01-23 | — | — | EP | disclosed |
| US-4400465-A | FROM ANIMAL INSULIN BY EXCHANGING THE B30 ALANINE WITH THREONINE | SHIONOGI & CO., LTD. (JP) | 1983-08-23 | — | — | US | disclosed |
| EP-0017938-B1 | PROCESS FOR PREPARING A B30-THREONINE INSULIN | SHIONOGI & CO., LTD. (JP) | 1983-08-03 | — | — | EP | disclosed |
| US-4320196-A | ENZYMATIC CATALYZED REACTION WITH THREONINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 1982-03-16 | — | — | US | disclosed |
| EP-0017938-A1 | Process for preparing a B30-threonine insulin | SHIONOGI & CO., LTD. (JP) | 1980-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189401-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | SERPINC1, F8, F9 | MMP9 949/4885MMP2 1308/4885TDP1 2132/4885 |
| US-20250186563-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | SERPINC1, F8, F9 | MMP9 949/4885MMP2 1308/4885TDP1 2132/4885 |
| US-20240082367-A1 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | SERPINC1, F13B, F2 | MMP9 283/4885MMP2 208/4885TDP1 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.